ArticleThe British journal of dermatology2020
The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema.
Article in The British journal of dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Phototherapy for atopic eczema.The Cochrane database of systematic reviews · 2021Pooled it
- Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.The British journal of dermatology · 2023Trial
- A New Phototherapy Regimen Coupled with Oral Vitamin D Supplementation, for the Long-Term Control of Atopic Dermatitis: A French Multicenter, Randomized, Crossover, Pragmatic Trial.Dermatology and therapy · 2026Article
- Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Observational
- Happiness across the borders-A cross-sectional study among patients with psoriasis and atopic dermatitis in Europe.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Eczema: etiology, subtypes, therapeutic approaches and socioeconomic impact.Frontiers in allergy · 2025Review
- Skin Barrier Repair and Nursing Care in Patients with Atopic Dermatitis: A Narrative Review.International journal of general medicine · 2025Review
- Article
- Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics.Journal of clinical medicine · 2023Article
- Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.JAMA dermatology · 2023Article
- Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce.Journal of the European Academy of Dermatology and Venereology : JEADV · 2023Article
- Real-world treatment patterns for atopic dermatitis in South Korea.Scientific reports · 2022Observational
- Treatment Patterns and Healthcare Resource Utilization Among Patients with Atopic Dermatitis: A Retrospective Cohort Study Using German Health Claims Data.Dermatology and therapy · 2022Article
- Drug survival of systemic immunosuppressive treatments for atopic dermatitis in a long-term pediatric cohort.International journal of women's dermatology · 2021Article
- Current Perspectives on the Systemic Management of Atopic Dermatitis.Journal of asthma and allergy · 2021Review
- Consensus on the therapeutic management of atopic dermatitis ‒ Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique.Anais brasileiros de dermatologiaArticle
Corrections and comments
- Commented on by
Authors and funding
11 authors at 6 institutions in 6 countries.
Funding
Abstract
backgroundFor many years dermatologists have had access to few therapies for patients with moderate-to-severe atopic eczema (AE). New promising therapies are entering the market but conventional phototherapies and systemic therapies have more well-known safety profiles, lower costs and wider availability.
objectivesTo provide insight into current prescribing practices of conventional phototherapy and systemic immunomodulatory therapies for adults with chronic AE, and the factors influencing these prescribing practices, before biologics and other novel therapeutics become routine clinical practice.
methodsIn this exploratory study dermatologists were invited to participate in an online survey via a mailing list of the European Academy of Dermatology and Venereology and national societies. Data were collected on participant characteristics (including clinical practice data), the use of phototherapies and systemic therapies, and factors influencing their use.
resultsFrom 30 European countries, 238 out of 361 dermatologists willing to participate (65·9%) completed the survey, with 229 meeting the inclusion criteria. For phototherapy (prescribed by 84·7%), most preferred narrowband ultraviolet B as first line (80·9%) and psoralen plus ultraviolet A as second (21·6%). For systemic therapy (prescribed by 95·2%) ciclosporin (54·1%), oral corticosteroids (32·6%) and methotrexate (30·7%) were used first line. Dermatologists relied mostly on personal experience for prescribing phototherapy and systemic therapy. Azathioprine and mycophenolic acid were prescribed by only 135 (59·0%) and 85 (37·1%) participants in total, mostly due to a lack of personal experience.
conclusionsThis study provides insight into prescribing practices for conventional phototherapy and systemic therapy in Europe and shows that off-label therapies are also preferred as first-line choice of systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.